Search research articles
Contact Us
Filters
Showing results (121-130 of 153) with videos related to
Page
of 16
Sort By:
Journal for Immunotherapy of Cancer
|
December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.
Nature Medicine
|
June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
The Journal of Clinical Investigation
|
June 4, 2013
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth
Yael Nemlich, Eyal Greenberg, Rona Ortenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2013
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies
Michal J Besser, Ronnie Shapira-Frommer, Orit Itzhaki, et al.
The Lancet. Oncology
|
July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert, Antoni Ribas, Jacob Schachter, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
JAMA Oncology
|
July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
Igor Puzanov, Antoni Ribas, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
Omid Hamid, Igor Puzanov, Reinhard Dummer, et al.
The Lancet. Oncology
|
March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Omid Hamid, Caroline Robert, Adil Daud, et al.
Page
of 16
Search research articles
Search
Showing results (121-130 of 153) with videos related to
Sort By:
Page
of 16
Journal for Immunotherapy of Cancer
|
December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.
Nature Medicine
|
June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
The Journal of Clinical Investigation
|
June 4, 2013
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth
Yael Nemlich, Eyal Greenberg, Rona Ortenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2013
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies
Michal J Besser, Ronnie Shapira-Frommer, Orit Itzhaki, et al.
The Lancet. Oncology
|
July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert, Antoni Ribas, Jacob Schachter, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
JAMA Oncology
|
July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
Igor Puzanov, Antoni Ribas, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
Omid Hamid, Igor Puzanov, Reinhard Dummer, et al.
The Lancet. Oncology
|
March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Omid Hamid, Caroline Robert, Adil Daud, et al.
Page
of 16